Common Contracts
2 similar License Agreement contracts by Adventrx Pharmaceuticals Inc
ContractLicense Agreement • May 5th, 2020 • Texas
EX-10.2 4 c14941exv10w2.htm EXHIBIT 10.2 Exhibit 10.2 LICENSE AGREEMENT THIS LICENSE AGREEMENT (this “Agreement”) is made and is effective as of June 8, 2004, (the “Effective Date”) between SynthRx, Inc. a Delaware corporation (“SynthRx”) and CytRx Corporation, a Delaware corporation (“CytRx”) with reference to the following facts: A. CytRx has developed CytRx Know-How (as hereinafter defined) and has CytRx Patent Rights (as hereinafter defined) in the fields of: (i) the composition and use of surface-active copolymers exemplified by poloxamer 188 to treat ischemic or damaged tissue, myocardial damage, stroke, pathological hydrophobic interactions in biological fluids, tissue damaged by reperfusion injury, sickle cell disease, cancer and in performing angioplasty procedures (with the CytRx Know-How and CytRx Patent Rights in this field referred to collectively as the “FLOCOR Intellectual Property”); (ii) the composition and use of surface active copolymers (exemplified by poloxamers, r
LICENSE AGREEMENTLicense Agreement • April 11th, 2011 • Adventrx Pharmaceuticals Inc • Pharmaceutical preparations • Texas
THIS LICENSE AGREEMENT (this “Agreement”) is made and is effective as of June 8, 2004, (the “Effective Date”) between SynthRx, Inc. a Delaware corporation (“SynthRx”) and CytRx Corporation, a Delaware corporation (“CytRx”) with reference to the following facts:
